SynthesisNeurosurgical review2020
Telomerase activity, TERT expression, hTERT promoter alterations, and alternative lengthening of the telomeres (ALT) in meningiomas - a systematic review.
Synthesis in Neurosurgical review, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- LncRNA TERRA in hybrid with DNA is a relevant biomarker for monitoring patients with meningioma.Scientific reports · 2025Article
- Is serum-derived exosomal hTERT transcript a marker of oncogenic activity in primary brain tumors? An exploratory study.Cancer medicine · 2024Article
- Epigenetic Downregulation of Hsa-miR-193b-3p Increases Cyclin D1 Expression Level and Cell Proliferation in Human Meningiomas.International journal of molecular sciences · 2023Article
- DNA methylation meningioma biomarkers: attributes and limitations.Frontiers in molecular neuroscience · 2023Review
- Prognostic significance of telomerase reverse transcriptase promoter gen mutations in high grade meningiomasBiomedica : revista del Instituto Nacional de Salud · 2022Article
- Review
- Advances in Molecular Biological and Translational Studies in World Health Organization Grades 2 and 3 Meningiomas: A Literature Review.Neurologia medico-chirurgica · 2022Review
- The genomic and transcriptional landscape of primary central nervous system lymphoma.Nature communications · 2022Article
- Circ_0000317/microRNA-520g/HOXD10 axis affects the biological characteristics of colorectal cancer.The Kaohsiung journal of medical sciences · 2021Article
- The overexpression of Tipe2 in CRC cells suppresses survival while endogenous Tipe2 accelerates AOM/DSS induced-tumor initiation.Cell death & disease · 2021Article
- Human TERT Promoter Mutations in Atypical and Anaplastic Meningiomas.Diagnostics (Basel, Switzerland) · 2021Article
- Intron 4-5 hTERT DNA Hypermethylation in Merkel Cell Carcinoma: Frequency, Association with Other Clinico-pathological Features and Prognostic Relevance.Endocrine pathology · 2021Article
- Predicting the risk of postoperative recurrence and high-grade histology in patients with intracranial meningiomas using routine preoperative MRI.Neurosurgical review · 2021Article
- hTERT promoter methylation promotes small cell lung cancer progression and radiotherapy resistance.Journal of radiation research · 2020Article
- Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Telomerase-Targeted Cancer Immunotherapy.International journal of molecular sciences · 2019Review
- Establishment of immortalized primary cell from the critically endangered Bonin flying fox (Pteropus pselaphon).PloS one · 2019Article
- Identification of shared genomic aberrations between angiomatous and microcystic meningiomas.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Telomerase activity and (human) Telomerase Reverse Transcriptase (hTERT) expression are considered hallmarks in oncogenesis of neoplasms and are upregulated by alterations of the hTERT promoter. In meningiomas, numerous studies investigated hTERT expression, telomerase activity, promoter mutations, and methylations. Moreover, reports about hTERT-targeted chemotherapy in meningiomas have recently been published. We provide a systematic review of the literature about the role of hTERT in meningiomas. TERT expression and telomerase activity is found in benign and high-grade meningiomas and increase with WHO grade. Remarkably, rates of TERT expression/telomerase activity usually exceed mutation frequency and both telomerase activity and TERT expression have also been found in hTERT promoter wildtype meningiomas, indicating further mechanisms of TERT upregulation. Although hTERT promoter methylation has been reported in the vast majority of meningiomas, correlation with TERT expression remains controversial. Rates of promoter mutations, and methylation were shown to increase with rising WHO grade. Moreover, promoter methylation and mutations strongly correlate with prognosis. Although mutations predicted malignant progression, de novo mutations in high-grade recurrences of former benign lesions were also observed. Retroviral transduction of the TERT gene enabled immortalization in several grade I-III meningioma cell lines. In vitro analyses revealed significant effects on viability in hTERT-mutated meningioma cells after targeted treatment. Alternative mechanisms of telomere lengthening are usually absent in meningiomas. TERT and hTERT promoter alterations play a major role during oncogenesis of meningiomas with implications for prognosis and potentially treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.